View conference programme - The British Society for Rheumatology

Janssen-Cilag
Janssen-Cilag Limited is a top-ten pharmaceutical company serving the United Kingdom. It has an outstanding record of
innovation and is a part of Johnson & Johnson, a family of around 190 healthcare companies active worldwide. Each has
its own mission and identity. Janssen-Cilag Ltd is the maker of DUROGESIC‘ (transdermal fentanyl) and TRAMACET 〉
(37.5mg tramadol Hcl and 325mg paracetamol).
Kyphon Europe
Kyphon focuses its energy in revolutionising spine therapy.
Balloon Kyphoplasty is a minimally invasive procedure to treat vertebral body compression fractures.
The technique is designed to reduce and stabilise the fracture in a controlled way, to correct spinal deformity and to provide
immediate pain relief and improved quality of life.
LCA SA
ARTHRUM H is a viscoelastic device specially designed for viscosupplementation of synovial fluid in osteoarthritic joints.
ARTHRUM H viscoelastic device is indicated for maintenance of endoarticular space, relief of pain and restoration of joint
mobility by replacing and providing viscoelastic supplementation of the diseased synovial fluid present in osteoarthritic joints.
MSD
Arcoxia ®
Merck Sharp & Dohme Limited (MSD) has a 60-year heritage in musculoskeletal research. Since 1936, when the company
introduced an early therapy for rheumatoid arthritis, MSD has made significant contributions to the development of new
medicines for arthritis and other musculoskeletal disorders, resulting in more than a dozen products including etoricoxib
(ARCOXIA ® ). MSD is the UK subsidiary of Merck & Co., Inc. of Whitehouse Station, New Jersey, USA – a leading researchbased
pharmaceutical company that develops, manufactures and markets a wide range of innovative pharmaceutical
products to improve human health.
MSD
Vioxx/Fosamax
Merck Sharp & Dohme Limited (MSD) have a 60-year heritage in musculoskeletal research. Since 1936, when the company
introduced an early therapy for rheumatoid arthritis, MSD has made significant contributions to the development of new
medicines for arthritis and other musculoskeletal disorders, resulting in more than a dozen products including rofecoxib
(VIOXX) and alendronate sodium (FOSAMAX). Both rofecoxib and alendronate sodium were discovered and developed by
MSD. MSD is the UK subsidiary of Merck and Co Inc of Whitehouse Station, New Jersey, USA a leading research based
pharmaceutical company that develops, manufactures and markets a wide range of innovative pharmaceutical products
to improve human health.
NASS
The National Ankylosing Spondylitis Society (NASS) was founded in 1976. It produces patient education material and has a
national network of over 100 branches providing supervised remedial physiotherapy one evening per week for approximately
2000 sufferers in one week.
It has provided the rheumatology profession and individual patients with over 110, 000 guide books.
NRAS
NRAS is a patient-led national Charity focussing specifically on Rheumatoid Arthritis.
Aims:
• Provision of a dedicated help-line and website advisory and information service
• Raising public, government and professional awareness of RA
• Campaigning for increased funding for the treatment and delivery of care in RA
• Promoting self-help in the management of the disease, informed choice and facilitating the
networking of patients
86